Trials / Unknown
UnknownNCT03781219
A PhaseI Study of HL-085 Plus Vemurafenib in Solid Tumor With BRAF V600 Mutation
A Phase I, Single Arm, Dose Escalation Study to Evaluate Safety, Pharmacokinetics and Preliminary Efficacy of HL-085 Plus Vemurafenib in Patients With BRAF V600 Mutant Advanced Solid Tumor
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 45 (estimated)
- Sponsor
- Shanghai Kechow Pharma, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase I, open-label, dose escalation study to evaluate tolerability, safety, pharmacokinetics and efficacy in patients with BRAF V600 mutant advanced solid tumor by HL-085 plus Vemurafenib treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HL-085 | HL-085 ( Capsule) is one MEK inhibitor. |
| DRUG | Vemurafenib | Vemurafenib ( Tablet) is BRAF inhibitor, |
Timeline
- Start date
- 2018-07-01
- Primary completion
- 2023-12-01
- Completion
- 2023-12-01
- First posted
- 2018-12-19
- Last updated
- 2023-05-31
Locations
4 sites across 1 country: China
Source: ClinicalTrials.gov record NCT03781219. Inclusion in this directory is not an endorsement.